When facing thousands of listed company announcements every day, which ones should you read? What are the key points to take away from the dozens or hundreds of pages of material announcements? Are the many professional terms in the announcements bullish or bearish? Check out Caixin's "Quick Read Announcement" column, where our reporters across the country will provide you with accurate, fast and professional interpretations on the night of the announcement.

On August 20th, Cailian Press (Reporter He Fan) Autobio Diagnostics (603658.SH) achieved double growth in H1 revenue and net profit, benefited from high R&D investment, initial results of some projects, and accelerated market expansion. It is worth noting that the proportion of the company's R&D expenses in the total revenue continues to increase, but the revenue proportion of the company's reagent sector has not increased as expected.

Autobio Diagnostics released its first-half report tonight, with H1 revenue of 2.207 billion yuan, a year-on-year increase of 4.7%; and a net profit of 620 million yuan attributable to shareholders of listed companies, a year-on-year increase of 13.49%.

Looking closely, Autobio Diagnostics' reagent sector achieved H1 operating income of 1.857 billion yuan, accounting for 84.14% of total revenue. At the earnings conference held earlier, the company's CFO, Ms. Feng Chao, said that "It is expected that the proportion of reagent products in the company will increase in the future." In H1 2023, the revenue proportion of the reagent sector accounted for 84.44% of total revenue. In the company's 2023 annual report, this proportion increased to 85.85%.

In the instrument sector, after the fully automatic biochemical analyzer AutoChem B801 series, Autobio Diagnostics obtained the medical instrument registration certificate for the high-throughput fully automatic biochemical analyzer AutoChem B2000 series. On July 20th, the company held a product launch conference online, officially releasing the AutoChem B2000 series and AutoChem B800 series.

In terms of R&D investment, Autobio Diagnostics continues to maintain its high investment strategy, and some projects have shown initial results. In the first half of this year, Autobio Diagnostics' R&D expenses were 333 million yuan, a year-on-year increase of 7.18%, accounting for 15.10% of revenue. Based on high R&D investment, the company made some progress in R&D in the first half of this year, with 74 new products registered (filed) in the reagent sector, covering fields such as magnetic particle chemiluminescence, chemiluminescence microparticle immunoassay, and molecular diagnosis. The detection projects cover autoimmune diseases, cardiovascular diseases, personalized medication, and so on. In addition, the company launched its own antibody detection series products, and 33 products in this series will be launched one after another in the first phase.

According to the announcement, the company's R&D investment in 2021-2023 is 485.9546 million yuan, 571.6948 million yuan, and 656,130,400 yuan, accounting for 12.90%, 12.87%, and 14.77% of the current operating income, respectively.

In addition, Autobio Diagnostics is involved in an overseas arbitration matter. On April 23rd, Autobio Diagnostics and its subsidiaries Antu Mobility and Antu Instrument initiated arbitration against Mobidiag Oy, and the International Court of Arbitration has accepted the case as of April 26th this year. The amount involved in the arbitration is estimated to be 50.7 million yuan.

At the same time, Autobio Diagnostics also announced today that it plans to add "molecular diagnostic reagents and key biological active materials (antigens, antibodies, etc.)" to the content of the "expanding the production capacity of in vitro diagnostic products" project. The company stated that this is to give full play to the synergies between the "molecular diagnostic reagent R&D platform" and "key biological active material (antigen, antibody, etc.) R&D platform" in the "in vitro diagnostic product R&D center project" to meet the production capacity expansion needs of the company's current related in vitro diagnostic reagent business.